• Supplemental Figure 1 
Definition of Confounders and Other Measured Covariates
The covariates were based on Read codes recorded in CPRD any time prior to index date. In addition, hypertension and obesity were also based on the following recorded values:
• Hypertension: blood pressure ≥140/90 mm Hg
• Obesity: body mass index ≥30 kg/m 2 Early-and moderate-stage CKD were defined in the following ways:
• Early-stage CKD: if a diagnosis code for stage 1 or 2 CKD was present or eGFR was ≥60 ml/min/1.73m² during the 12 months before index date
• Moderate-stage CKD: if there was a diagnosis code for stage 3 or 4 CKD or eGFR was 15-59 ml/min/1.73m² during the 12 months before index date For patients with 1 serum creatinine measurement recorded during the 12 months before index date, the closest measurement to index date was used to estimate eGFR and classify patients according to GFR category.
ICD-10 codes identifying CKD used in determination of death associated with CKD: Abbreviations: CKD, chronic kidney disease; IQR, interquartile range; N/A, not applicable; ULT, urate lowering therapy. Note. The study population includes both the gout and nongout cohorts. 28,435 patients were included in both cohorts (as matched nongout patients who subsequently developed gout became gout patients); information is provided on both exposures according to the different index dates.
a For the patients included in both cohorts, sex and Townsend score are reported once as they do not vary between being a nongout and a gout patient.
b Early-stage CKD defined as either a Read code for stage 1 or 2 CKD or an eGFR in the 12 months prior to study index date ≥60 ml/min (calculated using Chronic Kidney Disease Epidemiology Collaborative equation). Moderate-stage CKD defined as either a Read code for stage 3 or 4 CKD or an eGFR in the 12 months prior to study index date between 30 and 59 ml/min. Note. Patients with stage 5 CKD were excluded from the study. Supplemental Figure 1 . Sensitivity analyses illustrating association between gout and advanced chronic kidney disease and its four components, according to study population; main study population, incident gout and propensity score matched patients.
Supplemental
CKD, chronic kidney disease; PSM, propensity score matched; eGFR, estimated glomerular filtration rate; 95% CI, 95% confidence interval.
